Madopar

Levodopa/Benserazide, the active ingredient in Madopar, is a dopamine precursor and dopa‑decaboxylase inhibitor combination presented as an oral tablet for oral administration. It is indicated for the symptomatic treatment of Parkinson's disease and Parkinsonian syndromes in adult patients.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential ant Parkinson agent for healthcare providers with consistent quality, regulatory compliance and support for global distribution.

Madopar, a dopamine precursor/dopa decarboxylase inhibitor combination, is used to manage disorders related to dopamine deficiency. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: reduces motor impairment in patients with drug‑induced or vascular parkinsonism. - Levodopa‑responsive Parkinsonian disorders: provides symptomatic relief when dopamine deficiency is a primary factor.

Madopar may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Nausea: gastrointestinal upset that may occur after dosing. - Vomiting: may accompany nausea, especially at treatment initiation. - Dizziness: sensation of light‑headedness, often related to blood pressure changes. - Orthostatic hypotension: drop in blood pressure upon standing, causing faintness. - Headache: mild to moderate head pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can be disabling. - Psychiatric disturbances: hallucinations, confusion or depression. - Severe hypotension: marked blood pressure fall leading to syncope. - Cardiac arrhythmias: irregular heart rhythms, particularly in susceptible patients. - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever and muscle rigidity.

When prescribing Madopar, clinicians should consider several precautionary measures to ensure safe and effective use. - Renal or hepatic impairment: dose may need adjustment and monitoring. - Cardiovascular disease: monitor blood pressure and heart rate for hypotension or arrhythmias. - Psychiatric history: observe for hallucinations or mood changes. - Concomitant MAO‑B inhibitors: avoid use within 14 days to prevent hypertensive crisis. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at below 25°C: keep in the original container, protect from moisture and light.

Madopar can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis. - Antipsychotics (e.g., haloperidol): can reduce dopaminergic effect and worsen Parkinsonism. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance orthostatic hypotension. - SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors. - Iron supplements: can impair levodopa absorption; separate dosing by at least 2 hours.